Mankind Pharma Q4 Revenue Up 11.8% YoY

Mankind Pharma reported Q4 FY26 revenue of ₹3,443 crore, an 11.8% YoY increase, with adjusted EBITDA margins at 27.1%.
Domestic business grew 13.4% YoY, driven by a 190 bps increase in chronic therapy share to ~40% and strong performance in cardiac and anti-diabetic segments.
The Consumer Healthcare segment grew 19.8% YoY, while exports saw muted 4.2% growth due to geopolitical headwinds.
The company outlined its strategy focused on scaling base business, expanding specialty chronic and OTC portfolios, and growing its super specialty BSV portfolio.